Scarica l'app Stockscreener
18.82
3.19%
-0.62
Dopo l'orario di chiusura:
18.90
0.075
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$19.45
Aprire:
$19.53
Volume 24 ore:
6.86M
Relative Volume:
1.98
Capitalizzazione di mercato:
$13.98B
Reddito:
$956.00K
Utile/perdita netta:
$-221.32M
Rapporto P/E:
-58.83
EPS:
-0.32
Flusso di cassa netto:
$-142.25M
1 W Prestazione:
-21.04%
1M Prestazione:
-34.32%
6M Prestazione:
+5.88%
1 anno Prestazione:
-1.65%
Intervallo 1D:
$18.71
$19.64
Intervallo di 1 settimana:
$18.71
$26.45
Portata 52W:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Confronta SMMT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.82 | 14.44B | 956.00K | -221.32M | -142.25M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.48 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.13 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.53 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
767.00 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
351.13 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
Summit Therapeutics Inc. Investors: Please contact the - GlobeNewswire
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study - The Globe and Mail
First disclosure of Phase II data for pumitamig - The Pharma Letter
Is Summit Therapeutics a Buy, Sell, or Hold Now? - Nasdaq
Akeso's Lung Cancer Drug Faces US Approval Hurdles - Finimize
Summit Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingJuly 2025 Highlights & Advanced Technical Analysis Signals - beatles.ru
SVP, US Marketing at Summit Therapeutics Inc. Job - Mediabistro
Summit's High-Profile Drug Flops And Shares Crash - Investor's Business Daily
Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health - TheStreet
Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts - Endpoints News
Top Midday Decliners - MarketScreener
Summit Therapeutics Enters Oversold Territory (SMMT) - Nasdaq
Transcript : Summit Therapeutics Inc.Special Call - MarketScreener
Summit Therapeutics: Dethroning Merck Was Never Going To Be Straightforward - Seeking Alpha
Summit Therapeutics Shares Plunge After Lung Cancer Drug Data Disappoints - MSN
Akeso Drops Most in 3 Months on Mixed Drug Data From US Partner - Bloomberg.com
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch - MSN
Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics - Yahoo Finance
Summit Therapeutics stock rises as H.C. Wainwright reiterates Buy rating - Investing.com
Summit Therapeutics Shares Tumble As Lung Cancer Drug Disappoints Abroad - Finimize
Summit Therapeutics Reveals Promising Phase III Trial Results - TipRanks
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences - Yahoo Finance
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Summit Therapeutics (SMMT) Maintains Buy Rating from HC Wainwrig - GuruFocus
Summit Therapeutics stock sinks after lung cancer drug data disappoints By Investing.com - Investing.com Canada
Summit Therapeutics stock sinks after lung cancer drug data disappoints - Investing.com
S&P 500 Futures Climb in Premarket Trading; Summit Therapeutics, AST SpaceMobile Lag - Barron's
Summit shares tumble on mixed data for lung cancer drug - MarketScreener
Summit Therapeutics Shares Fall Pre-Bell Following New Data From Late-Stage Study of Cancer Drug Candidate - MarketScreener
Summit Therapeutics: Buy Rating Affirmed on Strong HARMONi Study Results and Strategic Positioning - TipRanks
Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside - TipRanks
Mixed results for Summit’s ivonescimab - The Pharma Letter
Summit Therapeutics stock rating reiterated at Market Outperform by JMP - Investing.com
Summit Therapeutics (SMMT) Reports Promising Phase III Trial Dat - GuruFocus
Retail Traders Flock To Summit Therapeutics After New Cancer Drug Data Shows Survival Gains - Stocktwits
Longer-Term Follow-Up of Western Patients Analysis (DCO: Sept 2025) - Placera.se
Breakthrough: Novel Cancer Drug Extends Survival to 16.8 Months in Global Lung Cancer TrialKey Data Released - Stock Titan
Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster - statnews.com
16.8-Month Survival Breakthrough: Summit's Novel Cancer Drug Shows Promise in Global Lung Cancer Trial - Stock Titan
Developing predictive dashboards with Summit Therapeutics Inc. dataCPI Data & AI Based Buy/Sell Signal Reports - Newser
Market reaction to Summit Therapeutics Inc.’s recent news2025 Biggest Moves & Verified Entry Point Detection - Newser
How to read the order book for Summit Therapeutics Inc.Insider Buying & Real-Time Stock Price Movement Reports - Newser
Why Summit Therapeutics (SMMT) Is Up 9.6% After Phase III Ivonescimab Data Revealed at IASLC 2025 - simplywall.st
Is Summit Therapeutics Inc. vulnerable to short sellersWeekly Trade Summary & High Accuracy Investment Entry Signals - خودرو بانک
Does Summit Therapeutics Inc. offer margin of safety2025 Retail Activity & Long-Term Growth Portfolio Plans - 뉴스영
What are the analyst revisions for Summit Therapeutics Inc.Is EXFY stock a good investment in YEARJuly 2025 Levels & Daily Chart Pattern Signals - خودرو بانک
Analyzing drawdowns of Summit Therapeutics Inc. with statistical tools2025 Year in Review & Fast Gain Stock Trading Tips - Newser
Is Summit Therapeutics Inc. benefiting from innovation trendsWeekly Investment Recap & Safe Swing Trade Setup Alerts - خودرو بانک
What are Summit Therapeutics Inc.’s growth leversMarket Movers & Verified Swing Trading Watchlists - خودرو بانک
Ranking Summit Therapeutics Inc. among high performing stocks via toolsJuly 2025 PostEarnings & Verified Chart Pattern Signals - Newser
Can Summit Therapeutics Inc. recover in the next quarterWeekly Risk Report & Growth-Oriented Investment Plans - Newser
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Summit Therapeutics Inc Azioni (SMMT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
1.96%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):